Condition: HPV-unrelated Head and Neck Squamous Cell Carcinoma · Sponsor: Washington University School of Medicine
This multicenter, open-label, randomized phase 3 trial will determine if palbociclib and cetuximab (Arm 1) improves overall survival (OS) in comparison to cetuximab monotherapy (Arm 2) in patients with CDKN2A-altered, HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who experienced disease progression on a PD-1/L1 inhibitor (given as monotherapy or in combination with other therapy).
This description comes directly from the study's public registry record.
Douglas Adkins, M.D. · 314-747-8475 · dadkins@wustl.edu
Always discuss trial participation with your own doctor first.
| Sanford Worthington Medical Center | Worthington, Minnesota, United States | Not Yet Recruiting |
| Saint Luke's Hospital | Kansas City, Missouri, United States | Withdrawn |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Sanford Roger Maris Cancer Center | Fargo, North Dakota, United States | Recruiting |
| Sanford Medical Center | Sioux Falls, South Dakota, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04966481